Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Matrixyl (Palmitoyl Pentapeptide-4)
Overview
Matrixyl is a lipopeptide composed of a pentapeptide sequence (Lys-Thr-Thr-Lys-Ser) attached to a palmitic acid moiety to enhance dermal penetration. It is proposed to stimulate fibroblast activity and upregulate synthesis of extracellular matrix components including collagen types I and III, fibronectin, and hyaluronic acid.
Mechanism of Action
The peptide serves as a matrikine fragment mimetic, signaling tissue remodeling pathways in aged or photodamaged skin.
Research Summary & Key Findings
In vitro fibroblast culture studies have documented increased collagen mRNA and protein expression following exposure to palmitoyl pentapeptide-4. Small-scale human trials conducted by cosmetic manufacturers have reported improvements in fine wrinkles and skin firmness after 12 weeks of topical use, though independent validation in peer-reviewed dermatology literature is sparse. Histological evidence of dermal matrix changes in human skin biopsies remains limited.
Clinical Status
Matrixyl (Palmitoyl Pentapeptide-4) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Matrixyl"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Matrixyl"
Registered interventional and observational studies, including status and phase.
- PubChem: "Matrixyl"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Dermatology
Afamelanotide (Scenesse)
FDA ApprovedA synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with a substitution of norleucine a...
View detailsArgireline (Acetyl Hexapeptide-8)
InvestigationalArgireline is a synthetic six amino acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) designed to attenuate neurotransmitter...
View detailsMatrixyl 3000
InvestigationalMatrixyl 3000 is a proprietary combination of two lipopeptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapept...
View detailsMatrixyl Synthe'6 (Palmitoyl Tripeptide-38)
InvestigationalPalmitoyl tripeptide-38 is a synthetic lipopeptide designed to stimulate synthesis of six major constituents of the derm...
View detailsNo lawful pathway today
Matrixyl (Palmitoyl Pentapeptide-4) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.